ES2086229T3 - Procedimiento para la obtencion de preparados medicinales de accion retardada. - Google Patents

Procedimiento para la obtencion de preparados medicinales de accion retardada.

Info

Publication number
ES2086229T3
ES2086229T3 ES93912763T ES93912763T ES2086229T3 ES 2086229 T3 ES2086229 T3 ES 2086229T3 ES 93912763 T ES93912763 T ES 93912763T ES 93912763 T ES93912763 T ES 93912763T ES 2086229 T3 ES2086229 T3 ES 2086229T3
Authority
ES
Spain
Prior art keywords
procedure
delayed action
medicinal preparations
obtaining delayed
action medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93912763T
Other languages
English (en)
Inventor
Roland Rauchfuss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goedecke GmbH
Original Assignee
Goedecke GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goedecke GmbH filed Critical Goedecke GmbH
Application granted granted Critical
Publication of ES2086229T3 publication Critical patent/ES2086229T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

EL OBJETO DEL ANUNCIO DE PATENTE ES UN PROCESO CONTINUO PARA LA ELABORACION DE FORMAS DE MEDICAMENTO RETARDADAS POR MEDIO DE UN EXTRUSIONADOR.
ES93912763T 1992-05-22 1993-05-21 Procedimiento para la obtencion de preparados medicinales de accion retardada. Expired - Lifetime ES2086229T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4216948 1992-05-22

Publications (1)

Publication Number Publication Date
ES2086229T3 true ES2086229T3 (es) 1996-06-16

Family

ID=6459487

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93912763T Expired - Lifetime ES2086229T3 (es) 1992-05-22 1993-05-21 Procedimiento para la obtencion de preparados medicinales de accion retardada.

Country Status (11)

Country Link
US (1) US5792474A (es)
EP (1) EP0641195B1 (es)
AT (1) ATE136459T1 (es)
AU (1) AU4316393A (es)
DE (1) DE59302200D1 (es)
DK (1) DK0641195T3 (es)
ES (1) ES2086229T3 (es)
FI (1) FI110233B (es)
GR (1) GR3019734T3 (es)
HK (1) HK1005307A1 (es)
WO (1) WO1993024110A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19522899C1 (de) * 1995-06-23 1996-12-19 Hexal Pharmaforschung Gmbh Verfahren zum kontinuierlichen Ersintern eines Granulats
DE19705538C1 (de) * 1997-02-14 1998-08-27 Goedecke Ag Verfahren zur Trennung von Wirkstoffen in festen pharmazeutischen Zubereitungen
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004069138A2 (en) * 2003-02-03 2004-08-19 Novartis Ag Pharmaceutical formulation
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
EP1694304A2 (en) * 2003-12-04 2006-08-30 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾-冻凝方法
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20110059140A1 (en) * 2007-12-21 2011-03-10 Gerhard Winter Extruded rod-shaped devices for controlled release of biological substances to humans and animals
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
CN102821757B (zh) 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3492070A1 (en) 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
DE3024416C2 (de) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system

Also Published As

Publication number Publication date
GR3019734T3 (en) 1996-07-31
EP0641195B1 (de) 1996-04-10
WO1993024110A1 (de) 1993-12-09
DE59302200D1 (de) 1996-05-15
US5792474A (en) 1998-08-11
FI945465L (fi) 1994-11-21
HK1005307A1 (en) 1998-12-31
FI110233B (fi) 2002-12-31
ATE136459T1 (de) 1996-04-15
DK0641195T3 (da) 1996-08-05
FI945465A0 (fi) 1994-11-21
AU4316393A (en) 1993-12-30
EP0641195A1 (de) 1995-03-08

Similar Documents

Publication Publication Date Title
ES2086229T3 (es) Procedimiento para la obtencion de preparados medicinales de accion retardada.
ES2160124T3 (es) Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades.
CO4950529A1 (es) Dihidropirimidinas y productos que las contienen
AR019855A1 (es) Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica
DE3382641D1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
IT9020055A0 (it) Metodo per il mascheramento del sapore di farmaci
ES2115590T3 (es) Metodo de prevencion mediante retinoides de la piel envejecida.
ES2000428A4 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
ES2071986T3 (es) Enmascaramiento del sabor del ibuprofeno con revestimiento en lecho fluidificado.
ATE97570T1 (de) Arzneimittel zur verhuetung von sexuell uebertragbaren krankheiten.
DK0547952T3 (da) Anvendelse af modafinil til fremstilling af et antiisskæmisk lægemiddel
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
ES2080549T3 (es) Medicamentos a base de derivados de polihidroximetileno, procedimiento para su preparacion y empleo.
IT1231107B (it) Procedimento e dispositivo per la fabbricazione di lattine mediante stiramento.
ES2173923T3 (es) Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente.
ES2093774T3 (es) Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
DE3873327D1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
IT1261284B (it) Procedimento e apperecchiatura per il trattamento di fluidi biologici
ES2129068T3 (es) Tratamiento de productos alimentarios.
ITGE930053A1 (it) Dispositivo per la fabbricazione di ovatte.
ES2101317T3 (es) Medicamento para aumentar el nivel de testosterona.
ES2120962T3 (es) Composicion antivirica.
EP0584034A3 (en) Conjugates of cytotoxic drugs for the treatment of neoplastic diseases.
ES2094834T3 (es) Dispositivo para el lavado, para finalidades terapeuticas o de higiene, de conductos internos humanos o animales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 641195

Country of ref document: ES